Drug Shortage Report for CONTRAVE
Report ID | 218165 |
Drug Identification Number | 02472945 |
Brand name | CONTRAVE |
Common or Proper name | CONTRAVE |
Company Name | BAUSCH HEALTH, CANADA INC. |
Market Status | MARKETED |
Active Ingredient(s) | BUPROPION HYDROCHLORIDE NALTREXONE HYDROCHLORIDE |
Strength(s) | 90MG 8MG |
Dosage form(s) | TABLET (EXTENDED-RELEASE) |
Route of administration | ORAL ORAL |
Packaging size | n/a |
ATC code | A08AA |
ATC description | |
Reason for shortage | Delay in shipping of the drug. |
Anticipated start date | 2024-02-29 |
Actual start date | |
Estimated end date | 2024-03-08 |
Actual end date | 2024-02-01 |
Shortage status | Avoided shortage |
Updated date | 2024-02-05 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2150 BOUL. ST-ELZEAR OUEST LAVAL, QUEBEC CANADA H7L 4A8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2024-02-05 | French | Compare |
v3 | 2024-02-05 | English | Compare |
v2 | 2024-02-01 | French | Compare |
v1 | 2024-02-01 | English | Compare |
Showing 1 to 4 of 4